StreetInsider.com News Articles

Form 425 Barinthus Biotherapeutic Filed by: Barinthus Biotherapeutics plc.

Mon, 23 Feb 2026 06:30:00 -0500

si-local-file:///var/storage/secattach/20260223/26038850.html

Form 425 Barinthus Biotherapeutic Filed by: Barinthus Biotherapeutics plc.

Mon, 23 Feb 2026 06:30:00 -0500

si-local-file:///var/storage/secattach/20260223/26038850.html

Form 8-K Barinthus Biotherapeutic For: Feb 23

Mon, 23 Feb 2026 06:03:00 -0500

si-local-file:///var/storage/secattach/20260223/26038727.html

Form 8-K Barinthus Biotherapeutic For: Feb 23

Mon, 23 Feb 2026 06:03:00 -0500

si-local-file:///var/storage/secattach/20260223/26038727.html

Form 8-K Barinthus Biotherapeutic For: Dec 30

Tue, 06 Jan 2026 16:10:00 -0500

si-local-file:///var/storage/secattach/20260106/25813343.html

Form 8-K Barinthus Biotherapeutic For: Dec 30

Tue, 06 Jan 2026 16:10:00 -0500

si-local-file:///var/storage/secattach/20260106/25813343.html

Form 8-K Barinthus Biotherapeutic For: Dec 10

Wed, 10 Dec 2025 08:05:00 -0500

si-local-file:///var/storage/secattach/20251210/25721427.html

Form 8-K Barinthus Biotherapeutic For: Dec 10

Wed, 10 Dec 2025 08:05:00 -0500

si-local-file:///var/storage/secattach/20251210/25721427.html

Barinthus Bio reports Phase 1 celiac disease drug shows dose response

Wed, 10 Dec 2025 08:00:25 -0500

Barinthus Biotherapeutics plc (NASDAQ: BRNS) announced that its experimental celiac disease treatment VTP-1000 demonstrated a dose-dependent pharmacological effect in the single ascending dose portion of its Phase 1 clinical trial.

The trial enrolled 18 patients across three placebo-controlled cohorts testing ascending doses of VTP-1000. The drug was well tolerated at all dose levels with no treatment-related serious adverse events reported, according to the company's statement.

The single ascending dose portion of the AVALON trial showed pharmacological data with a dose-dependent effect. The multiple ascending dose portion of the trial, which includes a gluten challenge component, remains ongoing with results expected in the

Barinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease

Wed, 10 Dec 2025 08:00:00 -0500

VTP-1000, an antigen-specific immunotherapy to treat celiac disease, showed a dose-dependent pharmacological effect in the SAD portion of the trial
VTP-1000 was well-tolerated with no treatment-related SAEs
The MAD portion of the trial, which includes a gluten challenge, is ongoing

GERMANTOWN, Md., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), an immunology and inflammation (“I&I”) company focused on developing immune tolerance therapies with curative potential, today announced an update on its first-in-human Phase 1 trial of VTP-1000 in adults with celiac disease. In the single ascending dose (“SAD”)

Barinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease

Wed, 10 Dec 2025 08:00:00 -0500

VTP-1000, an antigen-specific immunotherapy to treat celiac disease, showed a dose-dependent pharmacological effect in the SAD portion of the trial
VTP-1000 was well-tolerated with no treatment-related SAEs
The MAD portion of the trial, which includes a gluten challenge, is ongoing

Barinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease

Wed, 10 Dec 2025 08:00:00 -0500

VTP-1000, an antigen-specific immunotherapy to treat celiac disease, showed a dose-dependent pharmacological effect in the SAD portion of the trial
VTP-1000 was well-tolerated with no treatment-related SAEs
The MAD portion of the trial, which includes a gluten challenge, is ongoing

Barinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease

Wed, 10 Dec 2025 08:00:00 -0500

VTP-1000, an antigen-specific immunotherapy to treat celiac disease, showed a dose-dependent pharmacological effect in the SAD portion of the trial
VTP-1000 was well-tolerated with no treatment-related SAEs
The MAD portion of the trial, which includes a gluten challenge, is ongoing

Barinthus Biotherapeutics (BRNS) PT Raised to $4 at H.C. Wainwright

Mon, 17 Nov 2025 06:48:36 -0500

H.C. Wainwright analyst Yi Chen raised the price target on Barinthus Biotherapeutics (NASDAQ: BRNS) to $4.00 (from $3.00) while maintaining a Buy rating.

Barinthus Biotherapeutics plc (BRNS) Tops Q3 EPS by 4c

Fri, 07 Nov 2025 16:20:08 -0500

Barinthus Biotherapeutics plc (NASDAQ: BRNS) reported Q3 EPS of ($0.36), $0.04 better than the analyst estimate of ($0.40).

For earnings history and earnings-related data on Barinthus Biotherapeutics plc (BRNS) click here.

Form 10-Q Barinthus Biotherapeutic For: Sep 30

Fri, 07 Nov 2025 07:41:00 -0500

si-local-file:///var/storage/secattach/20251107/25575155.html

Form 10-Q Barinthus Biotherapeutic For: Sep 30

Fri, 07 Nov 2025 07:41:00 -0500

si-local-file:///var/storage/secattach/20251107/25575155.html

Form 8-K Barinthus Biotherapeutic For: Nov 07

Fri, 07 Nov 2025 07:34:00 -0500

si-local-file:///var/storage/secattach/20251107/25575087.html

Form 8-K Barinthus Biotherapeutic For: Nov 07

Fri, 07 Nov 2025 07:34:00 -0500

si-local-file:///var/storage/secattach/20251107/25575087.html

Barinthus Bio Reports Third Quarter 2025 Financial Results and Updates on Corporate Developments

Fri, 07 Nov 2025 07:30:00 -0500

Single ascending dose data readout for VTP-1000 expected before the end of 2025
Enrollment advancing in multiple ascending dose part of the AVALON trial; data expected in the second half of 2026
Proposed combination with Clywedog Therapeutics Inc. (“Clywedog”) to strengthen and diversify the pipeline and broaden the Company’s base of high caliber institutional investors.

GERMANTOWN, Md., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), an immunology and inflammation (“I&I”) company focused on developing therapies that promote immune tolerance with curative potential, today announced its financial

Barinthus Bio Reports Third Quarter 2025 Financial Results and Updates on Corporate Developments

Fri, 07 Nov 2025 07:30:00 -0500

Single ascending dose data readout for VTP-1000 expected before the end of 2025
Enrollment advancing in multiple ascending dose part of the AVALON trial; data expected in the second half of 2026
Proposed combination with Clywedog Therapeutics Inc. (“Clywedog”) to strengthen and diversify the pipeline and broaden the Company’s base of high caliber institutional investors.

Barinthus Bio Reports Third Quarter 2025 Financial Results and Updates on Corporate Developments

Fri, 07 Nov 2025 07:30:00 -0500

Single ascending dose data readout for VTP-1000 expected before the end of 2025
Enrollment advancing in multiple ascending dose part of the AVALON trial; data expected in the second half of 2026
Proposed combination with Clywedog Therapeutics Inc. (“Clywedog”) to strengthen and diversify the pipeline and broaden the Company’s base of high caliber institutional investors.

Barinthus Bio Reports Third Quarter 2025 Financial Results and Updates on Corporate Developments

Fri, 07 Nov 2025 07:30:00 -0500

Single ascending dose data readout for VTP-1000 expected before the end of 2025
Enrollment advancing in multiple ascending dose part of the AVALON trial; data expected in the second half of 2026
Proposed combination with Clywedog Therapeutics Inc. (“Clywedog”) to strengthen and diversify the pipeline and broaden the Company’s base of high caliber institutional investors.

ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with Barinthus Therapeutics

Fri, 24 Oct 2025 11:00:00 -0500

SAN DIEGO, Oct. 24, 2025 /PRNewswire/ -- ChemDiv, a global provider of integrated drug discovery solutions, today announced that it will continue providing chemistry, computational, and clinical pharmacology support to Clywedog Therapeutics as the company enters into a definitive merger agreement with Barinthus Therapeutics (NASDAQ: BRNS). The combined entity will operate under the name Clywedog Therapeutics, Inc. and is expected

ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with Barinthus Therapeutics

Fri, 24 Oct 2025 11:00:00 -0500